Conformational fingerprinting with Raman spectroscopy reveals protein structure as a translational biomarker of muscle pathology

James J P Alix,Maria Plesia,Alexander P Dudgeon,Catherine A Kendall,Channa Hewamadduma,Marios Hadjivassiliou,Gráinne S Gorman,Robert W Taylor,Christopher J McDermott,Pamela J Shaw,Richard J Mead,John C Day,James J. P. Alix,Alexander P. Dudgeon,Catherine A. Kendall,Gráinne S. Gorman,Robert W. Taylor,Christopher J. McDermott,Pamela J. Shaw,Richard J. Mead,John C. Day

DOI: https://doi.org/10.1039/d4an00320a

2024-03-29

The Analyst

Abstract:Neuromuscular disorders are a group of conditions that can result in weakness of skeletal muscles. Examples include fatal diseases such as amyotrophic lateral sclerosis and conditions associated with high morbidity such as myopathies (muscle diseases). Many of these disorders are known to have abnormal protein folding and protein aggregates. Thus, easy to apply methods for the detection of such changes may prove useful diagnostic biomarkers. Raman spectroscopy has shown early promise in the detection of muscle pathology in neuromuscular disorders and is well suited to characterising the conformational profiles relating to protein secondary structure. In this work, we assess if Raman spectroscopy can detect differences in protein structure in muscle in the setting of neuromuscular disease. We utilise in vivo Raman spectroscopy measurements from preclinical models of amyotrophic lateral sclerosis and the myopathy Duchenne muscular dystrophy, together with ex vivo measurements of human muscle samples from individuals with and without myopathy. Using quantitative conformation profiling and matrix factorisation we demonstrate that quantitative 'conformational fingerprinting' can be used to identify changes in protein folding in muscle. Notably, myopathic conditions in both preclinical models and human samples manifested a significant reduction in α-helix structures, with concomitant increases in β-sheet and, to a lesser extent, nonregular configurations. Spectral patterns derived through non-negative matrix factorisation were able to identify myopathy with a high accuracy (79% in mouse, 78% in human tissue). This work demonstrates the potential of conformational fingerprinting as an interpretable biomarker for neuromuscular disorders.

chemistry, analytical

What problem does this paper attempt to address?

The problem this paper attempts to address is the detection of protein structural abnormalities in neuromuscular diseases (such as amyotrophic lateral sclerosis and myopathies). Specifically, the study aims to detect changes in the secondary structure of proteins in these diseases using Raman spectroscopy, in order to identify potential translatable biomarkers. Neuromuscular diseases are a complex and heterogeneous group of conditions, and diagnosing and monitoring these diseases is often challenging. Therefore, developing a simple and non-invasive method to detect protein structural changes associated with these diseases is of great significance for improving disease diagnosis and monitoring.

The main hypothesis of the study is that myopathies lead to changes in the secondary structure of proteins, which can be detected using Raman spectroscopy and used as a "conformational fingerprint" for disease identification. By analyzing data from preclinical models (such as mouse models of Duchenne muscular dystrophy and amyotrophic lateral sclerosis) and human samples, the researchers validated this hypothesis and demonstrated the potential of quantitative "conformational fingerprints" in identifying myopathies. The study shows that under myopathic conditions, there is a significant reduction in α-helix structures, while β-sheet and irregular conformations correspondingly increase. These findings suggest that Raman spectroscopy has potential applications in the diagnosis and monitoring of neuromuscular diseases.